Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 7Glioma 7Wilms Tumor 6Rhabdoid Tumor 6Osteosarcoma 6Neuroblastoma 6Neoplasm Metastasis 6Leukemia, Myeloid, Acute 6Breast Neoplasms 6Sarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Medulloblastoma 5Lymphoma, Non-Hodgkin 5Lung Neoplasms 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Ependymoma 5Rhabdomyosarcoma 4Prostatic Neoplasms 4Myelodysplastic Syndromes 4Lymphoma 4Central Nervous System Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Sarcoma, Ewing 2Pancreatic Neoplasms 2Ovarian Neoplasms 2

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × X-Rays × 30 days × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡